Cancer Drug Found to Aid Cell Regeneration After Spinal Cord Injury
(Baltimore, MD) - In a study published today in Science (e-publication ahead of print), a global research team reports that the cancer drug Taxol® (Paclitaxel) promotes the regeneration of injured nerve cells in the central nervous system (CNS) after spinal cord injury. Scientists from the Max Planck Institute of Neurobiology in Germany and the Kennedy Krieger Institute's International Center for Spinal Cord Injury in Maryland, together with colleagues at the University of Utrecht in the Netherlands and University of Miami in Florida, found that the drug reduces the major obstacles to neural cell repair in the spinal cord of injured rats.
After a spinal cord injury a number of factors are known to halt the regeneration of nerve cells, including a poor capacity of neurons to grow and the development of scar tissue. Microtubules, small protein tubes which compose the cells' cytoskeleton, are jumbled in an injured CNS nerve cell, preventing the regrowth of cells. Concurrently, neural tissue is lost and a strong scar tissue develops, which creates a barrier for regeneration of the severed nerve cells.
Scientists found that Taxol® (Paclitaxel) has a dual role in spinal cord repair. It stabilizes the microtubule so that the injured nerve cells regain their ability to grow. Interestingly, the same drug prevents the production of inhibitory substances in the scar tissue. The scar tissue, though reduced, will still develop at the site of injury and carrying out its protective function; yet growing nerve cells are now better able to cross this barrier.
In this study, scientists supplied Taxol® (Paclitaxel) to the rats via a miniature pump at the injury site immediately after a partial spinal cord lesion. Within a few weeks the animals showed significant improvement in their movements.
"The drug essentially reorganizes the cells' microtubules allowing them to ignore 'stop signs' and to regrow through diminished scar tissue," said Dr. Andres Hurtado, study author and research scientist in the International Center for Spinal Cord Injury at Kennedy Krieger Institute. "It is a breakthrough for the cells and it puts us on a very promising path."
As a clinically approved drug for cancer treatment, Taxol® (Paclitaxel) has many advantages, primarily that much is already known about its interactions with the human body, which can help to accelerate the path to human clinical trials. The drug can also be applied directly at the spinal cord injury site, requiring a lower dose. Further, since the drug dosage needed is far less than what is used in cancer therapy, it is likely to have lower side effects. However, the scientists caution that more basic research is needed before clinical trials, including studying whether Taxol® (Paclitaxel) is as effective when applied a few months post-injury.
About the International Center for Spinal Cord Injury at the Kennedy Krieger Institute
The International Center for Spinal Cord Injury (ICSCI) at the Kennedy Krieger Institute is dedicated to innovative research and restoration recovery of chronic spinal cord injury and paralysis in children and adults. The interdisciplinary team at ICSCI is committed to the philosophy that with the right combination of therapies, recovery is always possible-even many months or years after an injury. The center's therapy programs follow techniques that have shown great promise in helping individuals with chronic spinal cord injuries recover sensation, movement and independence, as well as achieve improved health and quality of life. For more information on ICSCI, visit www.spinalcordrecovery.org. For more information on Kennedy Krieger Institute, visit www.kennedykrieger.org.
Max Planck Institute of Neurobiology
+49 89 8578-3514
Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.
A free resource that provides access to information and support for individuals and families living with developmental disabilities.